Sensorion

Sensorion develops innovative therapies dedicated to the treatment of vestibular and cochlear pathologies. Our scientists are focused on :

Relieving acute symptoms such as vertigo and tinnitus,
Reducing impairments (loss of balance, hearing loss ...) related to permanent damage of the inner ear,
Restore, to the extent possible, the functions already impacted.
Beginning in 2015, Sensorion launched the first clinical trial (phase 1b) with SENS-111, an innovative treatment against acute vertigo. SENS-111 will initially be tested on healthy volunteers to determine pharmacokinetics and tolerability.

Two other programs are also in the final stages of preclinical testing and Sensorion continues further development through international collaborations with academic research teams and Pharma companies.

Type
Public
HQ
Montpellier, FR
Employees
16 (est)
Sensorion is headquartered in Montpellier, FR

Sensorion Locations

Montpellier, FR

Sensorion Metrics

Sensorion Summary

Market capitalization

€31.7 M

Closing share price

€4.95
Sensorion's latest market capitalization is €31.7 M.

Sensorion Market Value History

Sensorion Company Life